Therefore, similar to estrogen dependent breast cancer patients, 17βHSD1 inhibitors either alone or in combination with aromatase inhibitors may represent a novel approach for treating estrogen dependent lung cancer patients. This evidence concerns the gene CYP19A1 and breast carcinoma.